AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
The US Food and Drug Administration (FDA) issued an interim rule last month providing additional safeguards for children participating in clinical studies of FDA-regulated products. The rule, which has been issued in response to "expected increases in the enrollment of children in clinical investigations as a result of recent pediatric initiatives," grants institutional review boards(IRBs) permission to approve, suspend or terminate clinical studies based on the level of risk associated with the study. However, the rule allows IRBs to approve only those clinical investigations that are of better, or at least equivalent, therapeutic ...